Direct-to-Consumer Genetic Testing Market Size, Share & Trends Analysis Report By Test Type (Nutrigenomics Testing, Predictive Testing, Carrier Testing), By Technology, By Distribution Channel, By Region, And Segment Forecasts, 2023 To 2030

Genetic test have traditionally been interpreted or ordered in a medical or clinical research setting. However, the last few years has witnessed a high growth in DTC genetic tests that offer consumers with the opportunity to learn about genetic profiles without participation of healthcare professionals. A novel use of DTC genetic testing data is the surveillance and identification of individuals of interest. The rising interest in pharmacogenetics is anticipated to expand the DTC testing space. These tests could be considered the main path towards the implementation of precision and personalized medicine in clinics.

Illumina OmniExpress chip is the most popular SNP BeadArray device previously used by DTC genetic testing entities. This product is utilized by Ancestry, 23andMe, FamilyTreeDNA and MyHeritage. In 2017, 23andMe changed from utilizing the Illumina OmniExpress chip to a customized Illumina Global Screening Array (GSA) microarray. Moreover, FamilyTreeDNA and MyHeritage also switched to utilizing novel GSA products. Furthermore, it is anticipated that NGS would eventually exceed the SNP BeadArrays chip as the major technology utilized for DTC consumer hereditary testing. A major reason determining this shift would be the rising affordability of NGS reagents.

Furthermore, increasing public awareness about this testing is expected to increase the adoption of this test, resulting boost the market growth. For instance, according to MIT’s Technology Review, around 8% -26 million people of the U.S. population have already taken DNA tests. And it is expected that that number is expected to increase to over 100 million in the coming years. Key players have channeled their attention into developing high-quality DTC genetic testing products. This novel test assured to deliver accurate and effective hereditary test outcomes.

The market is moderately fragmented, with a large number of medium and large-sized companies accounting for the majority revenue of the market. These entities are undertaking various strategic initiatives to strengthen their market presence. For instance, in August 2021, Ancestry declared that it acquired a leading French genealogy company, Geneanet. Geneanet has a presence in more than 25 nations. Moreover, in January 2022, 23andMe announced that FDA approved its DTC Genetic Test on a hereditary prostate cancer marker. This approval was the company’s third cancer risk report clearance. Such initiatives are expected to boost market growth in the coming years.

DTC Genetic Testing Market Segmentation

Major players operating in the DTC genetic testing market include 23andMe, Family Tree DNA, Ancestry, Genesis HealthCare, EasyDNA, Veritas, Myriad Genetics Inc., Full Genomes Corporation, Inc., Living DNA Ltd., Color Health, Inc., and Others.